Literature DB >> 29936382

Redox-responsive chemosensitive polyspermine delivers ursolic acid targeting to human breast tumor cells: The depletion of intracellular GSH contents arouses chemosensitizing effects.

Xin Ji1, Qiao Tang1, Peng Pang2, Jianping Wu3, Thomas Brett Kirk3, Jiake Xu4, Dong Ma5, Wei Xue6.   

Abstract

Antitumor efficacy of ursolic acid (UA) is seriously limited due to its low hydrophilicity and needy bioavailability. To overcome these obstacles, chemosensitive polyspermine (CPSP) conjugated with UA and folic acid (FA) as a novel targeted prodrug was designed and successfully synthesized in this investigation. This prodrug not only showed high aqueous solubility, GSH-triggered degradation and good biocompatibility, but also exhibited better inhibition effect on the tumor cells proliferation in comparison with free UA. FA-CPSP-UA could down-regulate the generation of GSH and manifest excellent ability in enhancing antitumor efficacy. In addition, FA-CPSP-UA could inhibit the expression of MMP-9, which led to restricting MCF-7 cells migration. Taken together, the results indicated that FA-CPSP-UA, as a carrier, can efficiently deliver UA to folate receptor positive cancer cells and improve tumor therapy of UA by Chemosensitive effect.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Chemosensitivity; Polymeric prodrug; Targeted delivery; Ursolic acid

Mesh:

Substances:

Year:  2018        PMID: 29936382     DOI: 10.1016/j.colsurfb.2018.06.029

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  2 in total

1.  A novel redox-responsive ursolic acid polymeric prodrug delivery system for osteosarcoma therapy.

Authors:  Daijie Fu; Zhe Ni; Kerong Wu; Peng Cheng; Xiaofeng Ji; Guoyuan Li; Xifu Shang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

2.  ROS-responsive dimeric prodrug-based nanomedicine targeted therapy for gastric cancer.

Authors:  Jiachi Ma; Yuzhong Chen; Wanqing Liang; Lei Li; Jun Du; Chengwu Pan; Chensong Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.